<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03210766</url>
  </required_header>
  <id_info>
    <org_study_id>CAN 01</org_study_id>
    <nct_id>NCT03210766</nct_id>
  </id_info>
  <brief_title>Nabilone and THC/CBD for the Treatment of FBSS Refractory Pain</brief_title>
  <official_title>Nabilone and THC/CBD for the Treatment of FBSS Refractory Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gioacchino Calapai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera Universitaria Policlinico &quot;G. Martino&quot;</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the efficacy of oral administration of nabilone or
      THC/CBD administration in combination with spinal cord stimulation (SCS) in FBSS patients
      refractory to other available therapeutic strategies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Failed Back Surgery Syndrome (FBSS) is defined as: spinal pain of unknown origin either
      persisting despite surgical intervention or appearing after surgical intervention for spinal
      pain originally in the same topographical location.

      Several conditions have been identified as causes of FBSS: epidural fibrosis, canal stenosis
      (global or lateral), foraminal stenosis, retained disc fragment, recurrent disc herniation or
      degeneration, spinal instability, facet joint pain, sacroiliac joint pain, discitis, adhesive
      arachnoiditis and others.

      Can involve 20% to 40% of patients who have undergone lumbar spine surgery and 0.02% to 2% of
      the general population suffer from this syndrome.

      In FBSS symptoms are the persistence of low back pain, deterioration or recurrence of
      radiculopathy, sensory and/or motor deficit, sphincter dysfunction.

      Chronic opioid therapy does not improve long-term pain management. Similar issues can occur
      with conservative measures like peridural injections of steroids, intrathecal analgesic
      infusion and local anesthetics injections. Despite a large part of FBSS patients benefit of
      radio-frequency treatment and/or spinal cord stimulation (SCS), a small percentage of them
      doesn't report benefits.

      Pain could be treated by drugs modulating endocannabinoid system and it could represent a
      pharmacological option in a multimodal treatment approach for neuropathic pain.

      Authors present a retrospective case series documenting the efficacy and safety of oral
      administration of cannabinoids agonists (THC/CBD and nabilone) in 20 FBSS patients,
      presenting moderate to severe chronic pain that not responding to other treatment regimens.

      Cannabinoids agonists were administered in association with the practice of spinal cord
      stimulation (SCS).

      Other analgesic therapies were discontinued before the beginning of the treatment.

      The study was performed during the period between September 2014 and January 2016 and the
      duration was up to 12 months.

      Characteristics and severity of neuropathic pain were measured using the Douleur
      Neuropathique 4 questionnaire. The Brief Pain Inventory allows patients to rate the severity
      of their pain and the degree to which pain interferes with common dimensions of feeling and
      function.

      Patients aged between 45 and 69. All patients received a fixed dose of cannabinoid agonists:
      treatment was initiated with nabilone 1mg/day or an oleic suspension for oral administration
      of THC/CBD 25mg/day.

      The basal dose was increased depending on effects on pain control. Adverse reactions were
      treated by decreasing the subscripted dose. If adverse events required the suspension of the
      administration of the initially prescribed drug, the same was switched with the other
      available in the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2014</start_date>
  <completion_date type="Actual">January 31, 2016</completion_date>
  <primary_completion_date type="Actual">January 1, 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Brief Pain Inventory (BPI)</measure>
    <time_frame>2015/1 to 2016/1</time_frame>
    <description>The Brief Pain Inventory allows patients to rate the severity of their pain and the degree to which their pain interferes with common dimensions of feeling and function. BPI has been shown to be an appropriate measure for pain caused by a wide range of clinical conditions. The BPI is an 11-item questionnaire that consists of four 0- to-10 numeric rating scale (NRS) items asking patients to rate their pain at its &quot;worst in the last 24-hours,&quot; least in the last 24-hours,&quot; &quot;average,&quot; and &quot;now,&quot; with a 0 indicating &quot;no pain&quot; and 10 representing &quot;pain as bad as you could imagine.&quot; The remaining seven BPI items probe the degree to which pain interferes with general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life, again using a 0-to-10 value scale. For these interference items, 0 represents &quot;does not interfere&quot; and 10 indicates &quot;interferes completely.&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Douleur Neuropathique-4 (DN-4)</measure>
    <time_frame>2015/1 to 2016/1</time_frame>
    <description>The DN4 questionnaire consists of a total of 10 items: 7 items related to the characteristics of pain (burning, painful cold, electric shocks) and its association with abnormal sensations (tingling, pins and needles, numbness, itching), and 3 related to neurological examination in the painful area (touch hypesthesia, pinprick hypesthesia, tactile allodynia). The value of 1 was given to each positive item, and 0 value to each negative item. The total score was calculated as the sum of all 10 items and the cutoff value for the diagnosis of neuropathic pain is established as a total score of 4/10.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">20</enrollment>
  <condition>FBSS</condition>
  <arm_group>
    <arm_group_label>Nabilone</arm_group_label>
    <description>Patients affected by Failed Back Surgery Syndrome (FBSS)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>THC/CBD</arm_group_label>
    <description>Patients affected by Failed Back Surgery Syndrome (FBSS)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nabilone</intervention_name>
    <arm_group_label>Nabilone</arm_group_label>
    <other_name>Spinal Cord Stimulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>THC/CBD</intervention_name>
    <arm_group_label>THC/CBD</arm_group_label>
    <other_name>Spinal Cord Stimulation</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients that comes to the pain unit, suffer from FBSS refractory pain
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  FBSS with refractory pain

          -  DN-4 score of 4 or +

        Exclusion Criteria:

          -  Adverse Drug Reaction

          -  Subject suffers from FBSS that could not quit the previous pharmacological therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Domenico Quattrone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>S. Vincenzo Hospital ASP Messina</affiliation>
  </overall_official>
  <reference>
    <citation>Burton CV, Kirkaldy-Willis WH, Yong-Hing K, Heithoff KB. Causes of failure of surgery on the lumbar spine. Clin Orthop Relat Res. 1981 Jun;(157):191-9.</citation>
    <PMID>7249453</PMID>
  </reference>
  <reference>
    <citation>Waguespack A, Schofferman J, Slosar P, Reynolds J. Etiology of long-term failures of lumbar spine surgery. Pain Med. 2002 Mar;3(1):18-22.</citation>
    <PMID>15102214</PMID>
  </reference>
  <reference>
    <citation>Slipman CW, Shin CH, Patel RK, Isaac Z, Huston CW, Lipetz JS, Lenrow DA, Braverman DL, Vresilovic EJ Jr. Etiologies of failed back surgery syndrome. Pain Med. 2002 Sep;3(3):200-14; discussion 214-7.</citation>
    <PMID>15099254</PMID>
  </reference>
  <reference>
    <citation>Krishna M, Pollock RD, Bhatia C. Incidence, etiology, classification, and management of neuralgia after posterior lumbar interbody fusion surgery in 226 patients. Spine J. 2008 Mar-Apr;8(2):374-9. Epub 2006 Dec 22.</citation>
    <PMID>17433779</PMID>
  </reference>
  <reference>
    <citation>Hussain A, Erdek M. Interventional pain management for failed back surgery syndrome. Pain Pract. 2014 Jan;14(1):64-78. doi: 10.1111/papr.12035. Epub 2013 Feb 3. Review.</citation>
    <PMID>23374545</PMID>
  </reference>
  <reference>
    <citation>Choi HS, Chi EH, Kim MR, Jung J, Lee J, Shin JS, Ha IH. Demographic characteristics and medical service use of failed back surgery syndrome patients at an integrated treatment hospital focusing on complementary and alternative medicine: a retrospective review of electronic medical records. Evid Based Complement Alternat Med. 2014;2014:714389. doi: 10.1155/2014/714389. Epub 2014 Nov 4.</citation>
    <PMID>25530787</PMID>
  </reference>
  <reference>
    <citation>Shapiro CM. The failed back surgery syndrome: pitfalls surrounding evaluation and treatment. Phys Med Rehabil Clin N Am. 2014 May;25(2):319-40. doi: 10.1016/j.pmr.2014.01.014. Review.</citation>
    <PMID>24787336</PMID>
  </reference>
  <reference>
    <citation>Thomson S. Failed back surgery syndrome - definition, epidemiology and demographics. Br J Pain. 2013 Feb;7(1):56-9. doi: 10.1177/2049463713479096.</citation>
    <PMID>26516498</PMID>
  </reference>
  <reference>
    <citation>Peul WC, van Houwelingen HC, van den Hout WB, Brand R, Eekhof JA, Tans JT, Thomeer RT, Koes BW; Leiden-The Hague Spine Intervention Prognostic Study Group. Surgery versus prolonged conservative treatment for sciatica. N Engl J Med. 2007 May 31;356(22):2245-56.</citation>
    <PMID>17538084</PMID>
  </reference>
  <reference>
    <citation>Chan CW, Peng P. Failed back surgery syndrome. Pain Med. 2011 Apr;12(4):577-606. doi: 10.1111/j.1526-4637.2011.01089.x. Epub 2011 Apr 4. Review.</citation>
    <PMID>21463472</PMID>
  </reference>
  <reference>
    <citation>Khosravi MB, Azemati S, Sahmeddini MA. Gabapentin versus naproxen in the management of failed back surgery syndrome; a randomized controlled trial. Acta Anaesthesiol Belg. 2014;65(1):31-7.</citation>
    <PMID>24988825</PMID>
  </reference>
  <reference>
    <citation>Zencirci B. Analgesic efficacy of oral gabapentin added to standard epidural corticosteroids in patients with failed back surgery. Clin Pharmacol. 2010;2:207-11. doi: 10.2147/CPAA.S12126. Epub 2010 Sep 30.</citation>
    <PMID>22291506</PMID>
  </reference>
  <reference>
    <citation>Abeloos L, De Witte O, Riquet R, Tuna T, Mathieu N. [Long-term outcome of patients treated with spinal cord stimulation for therapeutically refractory failed back surgery syndrome: a retrospective study]. Neurochirurgie. 2011 Jul;57(3):114-9. doi: 10.1016/j.neuchi.2011.07.001. Epub 2011 Sep 9. French.</citation>
    <PMID>21907361</PMID>
  </reference>
  <reference>
    <citation>Van Buyten JP, Al-Kaisy A, Smet I, Palmisani S, Smith T. High-frequency spinal cord stimulation for the treatment of chronic back pain patients: results of a prospective multicenter European clinical study. Neuromodulation. 2013 Jan-Feb;16(1):59-65; discussion 65-6. doi: 10.1111/ner.12006. Epub 2012 Nov 30.</citation>
    <PMID>23199157</PMID>
  </reference>
  <reference>
    <citation>North RB, Kidd D, Shipley J, Taylor RS. Spinal cord stimulation versus reoperation for failed back surgery syndrome: a cost effectiveness and cost utility analysis based on a randomized, controlled trial. Neurosurgery. 2007 Aug;61(2):361-8; discussion 368-9. Erratum in: Neurosurgery. 2009 Apr;64(4):601.</citation>
    <PMID>17762749</PMID>
  </reference>
  <reference>
    <citation>Sciubba DM, Gokaslan ZL. Spinal cord stimulation for failed back surgery syndrome--does it work and is it cost-effective? Nat Clin Pract Neurol. 2008 Sep;4(9):472-3. doi: 10.1038/ncpneuro0865. Epub 2008 Jul 22.</citation>
    <PMID>18648348</PMID>
  </reference>
  <reference>
    <citation>Boswell MV, Hansen HC, Trescot AM, Hirsch JA. Epidural steroids in the management of chronic spinal pain and radiculopathy. Pain Physician. 2003 Jul;6(3):319-34.</citation>
    <PMID>16880879</PMID>
  </reference>
  <reference>
    <citation>Kim SB, Lee KW, Lee JH, Kim MA, An BW. The effect of hyaluronidase in interlaminar lumbar epidural injection for failed back surgery syndrome. Ann Rehabil Med. 2012 Aug;36(4):466-73. doi: 10.5535/arm.2012.36.4.466. Epub 2012 Aug 27.</citation>
    <PMID>22977771</PMID>
  </reference>
  <reference>
    <citation>Kumar K, Hunter G, Demeria DD. Treatment of chronic pain by using intrathecal drug therapy compared with conventional pain therapies: a cost-effectiveness analysis. J Neurosurg. 2002 Oct;97(4):803-10.</citation>
    <PMID>12405366</PMID>
  </reference>
  <reference>
    <citation>Tomycz ND, Ortiz V, Moossy JJ. Simultaneous intrathecal opioid pump and spinal cord stimulation for pain management: analysis of 11 patients with failed back surgery syndrome. J Pain Palliat Care Pharmacother. 2010 Dec;24(4):374-83. doi: 10.3109/15360288.2010.523066.</citation>
    <PMID>21133746</PMID>
  </reference>
  <reference>
    <citation>Wong CB, Chen WJ, Chen LH, Niu CC, Lai PL. Clinical outcomes of revision lumbar spinal surgery: 124 patients with a minimum of two years of follow-up. Chang Gung Med J. 2002 Mar;25(3):175-82.</citation>
    <PMID>12022738</PMID>
  </reference>
  <reference>
    <citation>Duggal N, Mendiondo I, Pares HR, Jhawar BS, Das K, Kenny KJ, Dickman CA. Anterior lumbar interbody fusion for treatment of failed back surgery syndrome: an outcome analysis. Neurosurgery. 2004 Mar;54(3):636-43; discussion 643-4.</citation>
    <PMID>15028138</PMID>
  </reference>
  <reference>
    <citation>Kat'uch V, Pataky F, Kat'uchová J, Gajdos M, Radonak J. [Surgical management of the failed back surgery syndrome (FBSS) using posterior lumbar interbody fusion (PLIF) with posterior transpedicular stabilization]. Rozhl Chir. 2010 Aug;89(7):450-8. Slovak.</citation>
    <PMID>20925263</PMID>
  </reference>
  <reference>
    <citation>Simon A, Seizeur R, Person H, Forlodou P, Dam Hieu P, Besson G. [Anterior lumbar interbody fusion for treatment of failed back surgery syndrome: a retrospective study of 46 cases]. Neurochirurgie. 2009 Jun;55(3):309-13. doi: 10.1016/j.neuchi.2008.09.003. Epub 2008 Dec 16. French.</citation>
    <PMID>19091357</PMID>
  </reference>
  <reference>
    <citation>Esmer G, Blum J, Rulf J, Pier J. Mindfulness-based stress reduction for failed back surgery syndrome: a randomized controlled trial. J Am Osteopath Assoc. 2010 Nov;110(11):646-52. Erratum in: J Am Osteopath Assoc. 2011 Jan;111(1):3. J Am Osteopath Assoc. 2011 Jul;111(7):424.</citation>
    <PMID>21135196</PMID>
  </reference>
  <reference>
    <citation>Manniche C, Asmussen K, Lauritsen B, Vinterberg H, Karbo H, Abildstrup S, Fischer-Nielsen K, Krebs R, Ibsen K. Intensive dynamic back exercises with or without hyperextension in chronic back pain after surgery for lumbar disc protrusion. A clinical trial. Spine (Phila Pa 1976). 1993 Apr;18(5):560-7.</citation>
    <PMID>8484146</PMID>
  </reference>
  <reference>
    <citation>Katz JA, Swerdloff MA, Brass SD, Argoff CE, Markman J, Backonja M, Katz N. Opioids for chronic noncancer pain: A position paper of the American Academy of Neurology. Neurology. 2015 Apr 7;84(14):1503-4. doi: 10.1212/WNL.0000000000001485.</citation>
    <PMID>25846999</PMID>
  </reference>
  <reference>
    <citation>Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol. 2011 Nov;72(5):735-44. doi: 10.1111/j.1365-2125.2011.03970.x. Review.</citation>
    <PMID>21426373</PMID>
  </reference>
  <reference>
    <citation>Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain. 2006 Apr;7(4):281-9.</citation>
    <PMID>16618472</PMID>
  </reference>
  <reference>
    <citation>Attal N, Bouhassira D. Pharmacotherapy of neuropathic pain: which drugs, which treatment algorithms? Pain. 2015 Apr;156 Suppl 1:S104-14. doi: 10.1097/01.j.pain.0000460358.01998.15. Review.</citation>
    <PMID>25789426</PMID>
  </reference>
  <reference>
    <citation>Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol. 2010 Aug;9(8):807-19. doi: 10.1016/S1474-4422(10)70143-5. Review.</citation>
    <PMID>20650402</PMID>
  </reference>
  <reference>
    <citation>Maier C, Baron R, Sommer C. [Neuropathic pain. How to open the blackbox]. Schmerz. 2015 Oct;29(5):479-80, 482-5. doi: 10.1007/s00482-015-0028-y. Review. German.</citation>
    <PMID>26264897</PMID>
  </reference>
  <reference>
    <citation>Baber Z, Erdek MA. Failed back surgery syndrome: current perspectives. J Pain Res. 2016 Nov 7;9:979-987. eCollection 2016. Review.</citation>
    <PMID>27853391</PMID>
  </reference>
  <reference>
    <citation>Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, Haythornthwaite JA, Jensen MP, Kerns RD, Ader DN, Brandenburg N, Burke LB, Cella D, Chandler J, Cowan P, Dimitrova R, Dionne R, Hertz S, Jadad AR, Katz NP, Kehlet H, Kramer LD, Manning DC, McCormick C, McDermott MP, McQuay HJ, Patel S, Porter L, Quessy S, Rappaport BA, Rauschkolb C, Revicki DA, Rothman M, Schmader KE, Stacey BR, Stauffer JW, von Stein T, White RE, Witter J, Zavisic S. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008 Feb;9(2):105-21. Epub 2007 Dec 11.</citation>
    <PMID>18055266</PMID>
  </reference>
  <reference>
    <citation>Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain. 2010 Sep;150(3):573-81. doi: 10.1016/j.pain.2010.06.019.</citation>
    <PMID>20705215</PMID>
  </reference>
  <reference>
    <citation>O'Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med. 2009 Oct;122(10 Suppl):S22-32. doi: 10.1016/j.amjmed.2009.04.007. Review.</citation>
    <PMID>19801049</PMID>
  </reference>
  <reference>
    <citation>Lynch ME, Ware MA. Cannabinoids for the Treatment of Chronic Non-Cancer Pain: An Updated Systematic Review of Randomized Controlled Trials. J Neuroimmune Pharmacol. 2015 Jun;10(2):293-301. doi: 10.1007/s11481-015-9600-6. Epub 2015 Mar 22. Review.</citation>
    <PMID>25796592</PMID>
  </reference>
  <reference>
    <citation>Tsang CC, Giudice MG. Nabilone for the Management of Pain. Pharmacotherapy. 2016 Mar;36(3):273-86. doi: 10.1002/phar.1709. Epub 2016 Feb 29. Review.</citation>
    <PMID>26923810</PMID>
  </reference>
  <reference>
    <citation>Atkinson TM, Rosenfeld BD, Sit L, Mendoza TR, Fruscione M, Lavene D, Shaw M, Li Y, Hay J, Cleeland CS, Scher HI, Breitbart WS, Basch E. Using confirmatory factor analysis to evaluate construct validity of the Brief Pain Inventory (BPI). J Pain Symptom Manage. 2011 Mar;41(3):558-65. doi: 10.1016/j.jpainsymman.2010.05.008. Epub 2010 Dec 4.</citation>
    <PMID>21131166</PMID>
  </reference>
  <reference>
    <citation>Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention. Lancet. 2006 May 13;367(9522):1618-25. Review.</citation>
    <PMID>16698416</PMID>
  </reference>
  <reference>
    <citation>Ware MA, Doyle CR, Woods R, Lynch ME, Clark AJ. Cannabis use for chronic non-cancer pain: results of a prospective survey. Pain. 2003 Mar;102(1-2):211-6.</citation>
    <PMID>12620613</PMID>
  </reference>
  <reference>
    <citation>Pertwee RG. Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3353-63. doi: 10.1098/rstb.2011.0381. Review.</citation>
    <PMID>23108552</PMID>
  </reference>
  <reference>
    <citation>Stout SM, Cimino NM. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 2014 Feb;46(1):86-95. doi: 10.3109/03602532.2013.849268. Epub 2013 Oct 25. Review.</citation>
    <PMID>24160757</PMID>
  </reference>
  <reference>
    <citation>Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl). 1982;76(3):245-50.</citation>
    <PMID>6285406</PMID>
  </reference>
  <reference>
    <citation>Booz GW. Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress. Free Radic Biol Med. 2011 Sep 1;51(5):1054-61. doi: 10.1016/j.freeradbiomed.2011.01.007. Epub 2011 Jan 14. Review.</citation>
    <PMID>21238581</PMID>
  </reference>
  <reference>
    <citation>Fernández-Ruiz J, Sagredo O, Pazos MR, García C, Pertwee R, Mechoulam R, Martínez-Orgado J. Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? Br J Clin Pharmacol. 2013 Feb;75(2):323-33. doi: 10.1111/j.1365-2125.2012.04341.x. Review.</citation>
    <PMID>22625422</PMID>
  </reference>
  <reference>
    <citation>Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci. 2009 Oct;30(10):515-27. doi: 10.1016/j.tips.2009.07.006. Epub 2009 Sep 2. Review. Erratum in: Trends Pharmacol Sci. 2009 Dec;30(12):609.</citation>
    <PMID>19729208</PMID>
  </reference>
  <reference>
    <citation>Hayakawa K, Mishima K, Hazekawa M, Sano K, Irie K, Orito K, Egawa T, Kitamura Y, Uchida N, Nishimura R, Egashira N, Iwasaki K, Fujiwara M. Cannabidiol potentiates pharmacological effects of Delta(9)-tetrahydrocannabinol via CB(1) receptor-dependent mechanism. Brain Res. 2008 Jan 10;1188:157-64. Epub 2007 Oct 12.</citation>
    <PMID>18021759</PMID>
  </reference>
  <reference>
    <citation>Casarotto PC, Gomes FV, Resstel LB, Guimarães FS. Cannabidiol inhibitory effect on marble-burying behaviour: involvement of CB1 receptors. Behav Pharmacol. 2010 Jul;21(4):353-8.</citation>
    <PMID>20695034</PMID>
  </reference>
  <reference>
    <citation>Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley PJ. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2007 Dec;152(7):1092-101. Epub 2007 Sep 17.</citation>
    <PMID>17876302</PMID>
  </reference>
  <reference>
    <citation>Russo EB, Burnett A, Hall B, Parker KK. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res. 2005 Aug;30(8):1037-43.</citation>
    <PMID>16258853</PMID>
  </reference>
  <reference>
    <citation>Pazos MR, Mohammed N, Lafuente H, Santos M, Martínez-Pinilla E, Moreno E, Valdizan E, Romero J, Pazos A, Franco R, Hillard CJ, Alvarez FJ, Martínez-Orgado J. Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: role of 5HT(1A) and CB2 receptors. Neuropharmacology. 2013 Aug;71:282-91. doi: 10.1016/j.neuropharm.2013.03.027. Epub 2013 Apr 12.</citation>
    <PMID>23587650</PMID>
  </reference>
  <reference>
    <citation>Kathmann M, Flau K, Redmer A, Tränkle C, Schlicker E. Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Naunyn Schmiedebergs Arch Pharmacol. 2006 Feb;372(5):354-61. Epub 2006 Feb 18.</citation>
    <PMID>16489449</PMID>
  </reference>
  <reference>
    <citation>Esposito G, Scuderi C, Valenza M, Togna GI, Latina V, De Filippis D, Cipriano M, Carratù MR, Iuvone T, Steardo L. Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement. PLoS One. 2011;6(12):e28668. doi: 10.1371/journal.pone.0028668. Epub 2011 Dec 5.</citation>
    <PMID>22163051</PMID>
  </reference>
  <reference>
    <citation>Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimarães FS. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3364-78. doi: 10.1098/rstb.2011.0389. Review.</citation>
    <PMID>23108553</PMID>
  </reference>
  <reference>
    <citation>Costa B, Giagnoni G, Franke C, Trovato AE, Colleoni M. Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. Br J Pharmacol. 2004 Sep;143(2):247-50. Epub 2004 Aug 16.</citation>
    <PMID>15313881</PMID>
  </reference>
  <reference>
    <citation>Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, Moriello AS, Davis JB, Mechoulam R, Di Marzo V. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol. 2001 Oct;134(4):845-52.</citation>
    <PMID>11606325</PMID>
  </reference>
  <reference>
    <citation>Walitt B, Klose P, Fitzcharles MA, Phillips T, Häuser W. Cannabinoids for fibromyalgia. Cochrane Database Syst Rev. 2016 Jul 18;7:CD011694. doi: 10.1002/14651858.CD011694.pub2. Review.</citation>
    <PMID>27428009</PMID>
  </reference>
  <reference>
    <citation>Blumenthal DE, Malemud CJ. Recent strategies for drug development in fibromyalgia syndrome. Expert Rev Neurother. 2016 Dec;16(12):1407-1411. Epub 2016 Jul 14. Review.</citation>
    <PMID>27362466</PMID>
  </reference>
  <reference>
    <citation>Babson KA, Sottile J, Morabito D. Cannabis, Cannabinoids, and Sleep: a Review of the Literature. Curr Psychiatry Rep. 2017 Apr;19(4):23. doi: 10.1007/s11920-017-0775-9. Review.</citation>
    <PMID>28349316</PMID>
  </reference>
  <reference>
    <citation>Clark AJ, Lynch ME, Ware M, Beaulieu P, McGilveray IJ, Gourlay D. Guidelines for the use of cannabinoid compounds in chronic pain. Pain Res Manag. 2005 Autumn;10 Suppl A:44A-6A. Review.</citation>
    <PMID>16237482</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2017</study_first_submitted>
  <study_first_submitted_qc>July 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2017</study_first_posted>
  <last_update_submitted>July 5, 2017</last_update_submitted>
  <last_update_submitted_qc>July 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Universitaria Policlinico &quot;G. Martino&quot;</investigator_affiliation>
    <investigator_full_name>Gioacchino Calapai</investigator_full_name>
    <investigator_title>Associate Professor of Pharmacology</investigator_title>
  </responsible_party>
  <keyword>Cannabinoids, nabilone, FBSS, THC/CBD, refractory pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Intractable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nabilone</mesh_term>
    <mesh_term>Dronabinol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

